267900-42-5

Basic information

• Product Name: 1-O-(2-propenyl)-6-O-(4-tolylsulfonyl)-α-D-glucose
• Synonyms: 1-O-(2-propenyl)-6-O-(4-tolylsulfonyl)-α-D-glucose
• CAS NO: 267900-42-5
• Molecular Weight: 374.412
• Mol File: 267900-42-5.mol

Chemical Properties

• CAS DataBase Reference: 1-O-(2-propenyl)-6-O-(4-tolylsulfonyl)-α-D-glucose(CAS DataBase Reference)
• NIST Chemistry Reference: 1-O-(2-propenyl)-6-O-(4-tolylsulfonyl)-α-D-glucose(267900-42-5)
• EPA Substance Registry System: 1-O-(2-propenyl)-6-O-(4-tolylsulfonyl)-α-D-glucose(267900-42-5)

Safety Data

• Hazardous Substances Data: 267900-42-5(Hazardous Substances Data)

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 7464-56-4 1-O-allyl-α-D-glucopyranoside 
• 2280-44-6 D-Glucose 
• 93382-48-0 allyl 4,6-O-benzylidene-α-D-glucopyranoside 
• 1122-58-3 dmap 

Downstream Products

• 1234307-26-6 C₃₄H₅₂I₃O₁₂S^(1-)*Na⁽¹⁺⁾ 
• 1234307-25-5 C₅₂H₉₄I₃O₁₂SSi₃^(1-)*Na⁽¹⁺⁾ 
• 1234307-24-4 C₅₄H₉₇I₃O₁₀SSi₃ 
• 1234307-23-3 C₃₄H₅₄IO₁₂S^(1-)*Na⁽¹⁺⁾ 
• 1234307-22-2 C₅₂H₉₆IO₁₂SSi₃^(1-)*Na⁽¹⁺⁾ 
• 1234307-20-0 C₅₄H₉₉IO₁₀SSi₃ 
• 265312-92-3 1-O-allyl-2,3,4-tri-O-(tert-butyldimethylsilyl)-6-O-(4-tolylsulfonyl)-α-D-glucopyranoside 

Relevant articles and documents

Synthesis of sulfoquinovosylacylglycerols, inhibitors of eukaryotic DNA polymerase α and β

Sulfoquinovosyldiacylglycerols (SQDGs) and sulfoquinovosylmonoacylglycerols (SQMGs), bearing diverse fatty acids, were synthesized from d-glucose, and were examined for enzymatic inhibitions of DNA polymerase α and β. These results indicated that the carbon numbers of the fatty acids were highly related to the activities, at least in vitro, of eukaryotic DNA polymerase inhibition.

COMPOUND RETAINED IN TUMOR

A novel compound which specifically resides in a tumor, a method for allowing it to reside in a tumor, and a method for detecting, diagnosing, and treating tumor with use thereof are provided. The present invention relates to a compound represented by chemical formula (I) wherein R is an anionic group binding to hydrogen, R1 is OH, OCOH, OCO(CH2)hCH3, or an acting group, h being an integer of 0 or more, R2 is H, OH, OCOH, OCO(CH2)iCH3, or an acting group, i being an integer of 0 or more, R3 is OH, SO3H, or an acting group, R4 is OH, SO3H, or an acting group, and R5 is OH, SO3H, or an acting group, at least one of R1, R2, R3, R4, and R5 containing an acting group, or pharmaceutically acceptable salts thereof.

Sulfoquinovosylacylglycerol derivative, and use thereof as medicaments

A method for immunosuppression in a subject comprising administering to the subject in need thereof, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol derivative represented by General formula (1-1): wherein R101 represents an acyl residue of a higher fatty acid, and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid; and a pharmaceutically acceptable salt thereof. Of the sulfoquinovosylacylglycerol derivatives, β-sulfoquinovosylacylglycerols are novel compounds. The present invention also relates to pharmaceutical composition comprising a pharmaceutically effective amount of the β-sulfoquinovosylacylglycerols and/or its pharmaceutically acceptable salt; and a pharmaceutically acceptable excipient. The pharmaceutical composition may be used as an immunosuppressive agent, anticancer agent and DNA polymerase α inhibitor.

Medicament containing a sulfopyranosylacylglycerol derivative

A medicament containing at least one compound selected from the group consisting of compounds represented by General formula (1): wherein R101 represents an acyl residue of an unsaturated higher fatty acid, and R102 represents a hydr

Novel sulfoquinovosylacylglycerol derivative, and use thereof as medicaments

A method for immunosuppression in a subject comprising administering to the subject in need thereof, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol derivative represented by General formula (1-1): wherein R101 represents an acyl residue of a higher fatty acid, and R102 represents a hydrogen atom or an acyl residue of a higher fatty acid; and a pharmaceutically acceptable salt thereof. Of the sulfoquinovosylacylglycerol derivatives, β-sulfoquinovosylacylglycerols are novel compounds. The present invention also relates to pharmaceutical composition comprising a pharmaceutically effective amount of the β-sulfoquinovosylacylglycerols and/or its pharmaceutically acceptable salt; and a pharmaceutically acceptable excipient. The pharmaceutical composition may be used as an immunosuppressive agent, anticancer agent and DNA polymerase α inhibitor.